HLA-B and neoplasm: Tumor cells often employ various mechanisms to evade host adaptive immunosurveillance, such as reducing the expression of major histocompatibility complex (MHC) class 1 antigens, increasing inhibitory checkpoint molecules, and minimizing the presentation of tumor-associated and tumor-specific antigens [45].